Android app on Google Play

Notable Analyst Rating Changes 12/10: (CELG) (GERN) (ARIA) Upgraded; (DGX) (HME) (CHL) Downgraded

December 10, 2013 10:42 AM EST Send to a Friend
Credit Suisse moves Celgene (Nasdaq: CELG) from Neutral to Outperform.

Needham & Company boosts Geron Corporation (Nasdaq: GERN) from Hold to Buy with a price target of $10. Click Here for more color.

Stifel Nicolaus raises ARIAD Pharmaceuticals (Nasdaq: ARIA) from Hold to Buy with a $7 price target.

KLR Group upgrades Goodrich Petroleum (NYSE: GDP) from Accumulate to Buy, while maintaining its price target at $26.

For daily real-time Upgrades go to

BofA/Merrill Lynch cuts Quest Diagnostics (NYSE: DGX) from Buy to Underperform.

Morgan Stanley drops Home Properties (NYSE: HME) from Equalweight to Underweight.

Barclays slashes China Mobile (NYSE: CHL) from Overweight to Underweight.

Longbow Research lowers Old Dominion Freight Line (Nasdaq: ODFL) from Buy to Neutral and removed its $52 price target.

For daily real-time Downgrades go to

Zulily, Inc (Nasdaq: ZU) started by a handful today:
  • BofA/Merrill Lynch at Neutral and $39 price target;

  • William Blair at Outperform;

  • Citi with a Neutral rating and price target of $38;

  • RBC Capital with a Sector Perform and $40 price target; and

  • Goldman Sachs at Neutral and $36 price target.
Jefferies initiates Rambus Inc. (Nasdaq: RMBS) with a Buy and price target of $13. Click Here for more color.

Credit Suisse initiates Allegion (NYSE: ALLE) at Outperform and price target of $48.

Morgan Stanley starts Relypsa, Inc. (Nasdaq: RLYP) with an Overweight rating and price target of $57.

For daily real-time New Coverage go to

Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Credit Suisse, Stifel Nicolaus, William Blair, Citi, Morgan Stanley, Jefferies & Co, Merrill Lynch, Needham & Company, Bank of America, RBC Capital, Barclays, Longbow Research, Notable Analyst Rating Changes

Add Your Comment